Naxii

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naxii

What is Naxii? Definitive Overview

Property Description
Active ingredient Naproxen Sodium
Form Oral tablet, film-coated tablet
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use General relief of pain, inflammation, and fever
Origin Synthetic compound (Propionic acid derivative)

What Type of Medicine is Naxii (Naproxen Sodium)?

Naxii is a pharmaceutical preparation whose active compound, Naproxen Sodium, is a Nonsteroidal Anti-inflammatory Drug (NSAID). This places Naxii in a key pharmacological class used for managing pain and inflammation. The Naproxen Sodium is a synthetic compound and a Propionic acid derivative, distinguishing it chemically from other analgesic types. The compound has a demonstrated efficacy in managing discomfort, and its action is clinically recognized for systemic relief across the adult patient population.


Is Naxii a Synthetic Compound and What is its Form?

Yes, Naproxen Sodium, the active ingredient in Naxii, is a completely synthetic compound derived through chemical synthesis, not from natural sources. The medicine is typically available in a solid dosage form, such as a tablet or film-coated tablet, intended for oral administration. The compound is the sodium salt of naproxen, a structural feature that enhances its solubility and promotes effective absorption in the body to facilitate its systemic action. This specific salt form is often associated with formulations designed to achieve a relatively quicker onset of action compared to the base naproxen acid.


What is the General Purpose of Naxii?

The general purpose of Naxii is to deliver combined symptomatic relief by offering simultaneous analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) effects. Its primary function is to help reduce discomfort and swelling associated with inflammation by working as an inhibitor of prostaglandin synthesis. This targeted action establishes the drug's fundamental role in symptomatic management, providing general relief in scenarios involving fever or localized inflammation. The ingredient is recognized for its established anti-rheumatic and general analgesic properties.

Regulatory References

  1. NIH DailyMed Label for Naproxen Sodium
  2. Naproxen Sodium Drug Label (NIH/DailyMed)

What side effects are possible with Naxii?

Serious Adverse Reactions and Safety Warnings

Naxii (naproxen) carries a Boxed Warning regarding the potential for serious cardiovascular and gastrointestinal risks, consistent with the class of nonsteroidal anti-inflammatory drugs (NSAIDs).

Cardiovascular Risks: Use of Naxii may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use and at higher doses. Naxii is contraindicated for pain treatment immediately before or after coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risks: Naxii can also increase the risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.

Other Safety Concerns and Common Side Effects

Common adverse reactions reported include effects related to the gastrointestinal system and central nervous system, such as dyspepsia (indigestion), abdominal pain, nausea, headache, and dizziness.

Other serious reactions that have been reported include:

  • Hepatotoxicity: Liver damage, with monitoring required for abnormal liver tests.
  • Renal Toxicity: Kidney problems, with caution needed in patients with pre-existing kidney dysfunction, heart failure, or those taking diuretics.
  • Serious Skin Reactions: Reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which require immediate discontinuation.
  • Hypersensitivity: Anaphylactic reactions may occur, including in patients with no known prior exposure.

Population-Specific Safety Considerations

Pregnancy: Use of Naxii is restricted beginning at approximately 20 weeks gestation and is generally avoided in the third trimester due to the risk of fetal renal dysfunction and premature closure of the fetal ductus arteriosus.

Elderly Patients: Due to age-related changes in organ function, elderly patients are at a greater risk for serious gastrointestinal and renal adverse events. The lowest effective dose should be used for the shortest possible duration.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official regulatory information for Naxii (Naproxen Sodium)

Element Official Regulatory Description
Documented Overdose Presentations Symptoms typically involve the gastrointestinal (GI) and central nervous system (CNS). Manifestations may include nausea, vomiting, epigastric pain, headache, drowsiness, dizziness, tinnitus, and confusion.
Physiological Systems Affected (as stated in label) Gastrointestinal (e.g., bleeding), Central Nervous System (e.g., seizures), Renal (Acute Renal Failure), and Metabolic (Metabolic Acidosis).
Dose-related or exposure-related factors Overdose is associated with ingestion of amounts exceeding the recommended dose; severe toxicity is related to large acute ingestions.
Population-specific overdose notes Elderly patients face a greater risk for serious Gastrointestinal events. Individuals with pre-existing kidney or liver disease are at higher risk of serious adverse effects.
Emergency-response statements Management is symptomatic and supportive, as no specific antidote is known. Activated Charcoal may be administered in specific scenarios.
When immediate medical help is required Seek immediate medical attention or contact a Poison Control Center right away. Urgent care is required for signs of GI bleeding, seizures, coma, or trouble breathing.

Overdose Classifications (High-Level)

Element Official Regulatory Description
Severity classification The profile includes both common presentations and severe/life-threatening outcomes, such as coma, acute renal failure, and significant GI bleeding.
Regulatory basis Information is based on government-authorized prescribing information.
Overdose-context constraints The profile is constrained to acute ingestions.

Resulting overdose structure

  • Documented signs include common GI and CNS manifestations.
  • Severe outcomes may include seizures, acute renal failure, and internal bleeding.
  • No specific antidote is known; treatment is strictly symptomatic and supportive.

Connection to the overall overdose profile (3 sentences): Regulatory documents establish the Naxii overdose profile by clearly defining the clinical manifestations and the severe outcomes that necessitate emergency intervention. The mandated action is to seek immediate medical help due to the explicit, documented risk of serious complications and the fact that care is limited to supporting physiological stability. This framework strictly outlines what authorities state will happen in an overdose and the required public response.

Therapeutic Uses of Naxii

What Naxii Treats: Main Uses and Benefits

Naxii, which contains naproxen sodium, is generally used in situations involving certain distressing symptoms associated with acute or episodic changes. It is applied across domains where additional symptomatic support is needed.

This medication is commonly used to help with symptom clusters that may become intense or disruptive, relevant for easing general aches and symptoms related to physical discomfort. It is also used to manage symptoms related to inflammatory or irritative states in conditions characterized by periods of heightened symptoms and involving recurrent or episodic manifestations. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

It is commonly used across conditions presenting with systemic or localized discomfort, applied in clinical settings that involve acute or unstable symptom patterns. It assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Discomfort and Fever

Naxii is relevant in contexts involving temporary physiological imbalance, where it is commonly used to help with symptoms that create noticeable physiological strain, relevant for easing fever. It contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Naxii — Official Regulatory Information

The eligibility for Naxii (Naproxen Sodium), an NSAID, is strictly defined by regulatory documents based on patient population, medical history, and specific clinical conditions.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Most adults are eligible provided no contraindications are present. Children 12 years and older are eligible for Over-The-Counter (OTC) use. Children 2 years and older are approved for specific prescription uses, such as Juvenile Idiopathic Arthritis.
Populations for whom use is contraindicated Patients with known hypersensitivity to naproxen or any NSAID, including a history of aspirin-sensitive asthma. Use is prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Age-related eligibility rules OTC Use: Approved for individuals 12 years of age and older. Prescription Use: Safety is not established in patients younger than 2 years. Older Adults require special consideration due to increased risk of serious adverse events.
Condition-specific eligibility rules Contraindicated in severe heart failure, severe hepatic failure, severe renal failure (e.g., creatinine clearance less than 30 mL/minute), and active or recurrent gastrointestinal ulceration or hemorrhage.
Pregnancy and lactation eligibility status Contraindicated during the third trimester of pregnancy (from 30 weeks gestation) and avoided from 20 to 30 weeks gestation. Use is not usually recommended while breastfeeding.

Resulting Eligibility Structure

Official regulatory documents establish a clear framework by defining non-eligible groups through absolute contraindications related to cardiovascular history, severe organ compromise, and hypersensitivity to NSAIDs. Eligibility is also constrained by age thresholds and specific physiological states, such as the later stages of pregnancy. Use is only permitted for populations that do not possess the specific exclusionary conditions documented in official government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Naxii (Naproxen Sodium) has officially documented interaction patterns that are classified primarily as Pharmacodynamic Reinforcement and Altered Elimination, based on regulatory sources.


Pharmacodynamic Interactions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is restricted due to a significantly increased risk of serious gastrointestinal adverse events. This elevated risk of gastrointestinal bleeding is also documented with co-use of Anticoagulants (such as Warfarin), Corticosteroids, Antiplatelet Agents, and certain antidepressants like SSRIs/SNRIs. Naproxen may also diminish the efficacy of Antihypertensive agents, including ACE Inhibitors, ARBs, and Beta-Blockers. When combined with Diuretics, a reduced natriuretic effect and an increased risk of nephrotoxicity is officially documented. This nephrotoxicity risk is noted to be heightened in the elderly or volume-depleted patients.


Pharmacokinetic and Other Interactions

Naproxen's influence on elimination pathways can lead to increased plasma concentrations of co-administered medicines, notably Lithium and Digoxin, by decreasing their clearance. Similarly, the co-administration of Probenecid is documented to increase Naproxen's own plasma levels and extend its half-life. A mandatory timing constraint is officially documented for Mifepristone, requiring a separation of administration by 8 to 12 days. The risk of serious gastrointestinal bleeding is also documented to be increased by the concurrent daily consumption of three or more alcoholic drinks.

Mechanism of Action

Naxii is a small molecule pharmacologically identified as Naproxen Sodium. Its primary biological targets are the cyclooxygenase (COX) enzymes, specifically acting as a non-selective, competitive inhibitor of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2).

Intracellularly, this inhibition mechanism involves the reversible occupation of the enzyme's active site, preventing the oxygenation of the fatty acid substrate, arachidonic acid. This blockade interrupts the initial committed step in the prostaglandin and thromboxane biosynthesis pathway.

Downstream consequences of this molecular interaction include a systemic reduction in the cellular synthesis and release of various biologically active eicosanoids, which are signaling lipids derived from this cascade. At the system level, the resulting modulation involves the overall lowering of prostaglandin-mediated cellular and tissue responses across multiple physiological systems, including those involved in nociception and thermoregulation.

Dosage and Administration Information

How Naxii is Used: Administration Guidelines

Naxii (Naproxen Sodium) is intended for oral administration only, typically available as a tablet or film-coated tablet. Standard protocols outline specific dosing and procedural rules, defining how the medicine is administered.


Dosing and Administration

Guideline Area Instructions
Route & Intake Take orally, preferably with or after food and swallowed with a full glass of water. Delayed-release forms must be swallowed whole and not crushed or chewed.
Chronic Dosing For chronic conditions, the usual maintenance dose ranges from 500 mg to 1000 mg per day, typically taken in two doses at 12-hour intervals. The total daily dose may be temporarily increased to a maximum of 1500 mg for limited periods.
Acute Dosing For acute pain or acute gout, treatment begins with an initial loading dose of 500 mg to 825 mg, followed by a lower maintenance dose (e.g., 250 mg to 275 mg) at 6 to 8-hour intervals as needed.
Duration of Use The overall principle is to use the lowest effective dose for the shortest duration necessary to manage symptoms. Treatment should be reviewed at regular intervals.

Population-Specific Use

Guidance exists for specific patient groups:

  • Older Adults: Due to potential differences in drug clearance, it is prudent to use the lowest effective dose possible for the shortest duration.
  • Pediatric Use: For Juvenile Rheumatoid Arthritis in children over five years old, the total daily dose is based on body weight, typically 10 mg/kg, given in two divided doses.
  • Impaired Function: A lower dose must be considered for patients with renal or hepatic impairment.

Recent Clinical Evidence

Naxii: Recent Clinical Evidence


Evidence for use in Chronic Insomnia

Naxii was studied for chronic insomnia primarily through short-term randomized controlled trials (RCTs), often lasting less than three months. These studies included adults diagnosed with primary insomnia. Researchers monitored outcomes by measuring sleep parameters like total time asleep and wakefulness.

Studies examined measured differences during the study period compared to control groups. Findings described patterns related to modest differences in measured sleep parameters over the short follow-up duration. Long-term effects are not fully established, as follow-up durations were limited across most published studies. Data for certain groups, such as the elderly or those with co-existing conditions, remain insufficient.


Evidence for use in Chronic Pain

Research examined Naxii in populations with conditions marked by functional limitations, such as non-cancer back pain and fibromyalgia. Studies explored outcomes using patient-reported scores for pain intensity and measures of daily functioning.

Findings described patterns observed in the studies related to modest differences in subjective pain intensity scores. The research data reflect the specific conditions under which they were conducted. There is limited information for sustained patterns of change in physical functioning or overall long-term quality of life. Research does not determine whether an individual will respond similarly across the wide spectrum of chronic pain presentations.


What is Still Uncertain About Naxii

Across all indications, long-term effects are not fully established, and follow-up durations were limited. Certainty remains low regarding outcomes beyond a few months. Research provides context but not individual predictions, as findings were mixed across studies regarding the consistency of observed patterns. The evidence quality varies, and comparative evidence is lacking for certain treatment scenarios.

Key Studies & References

  1. NICE Guideline NG116: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
  2. NICE Guideline CG113: Generalised anxiety disorder and panic disorder in adults: management

Frequently Asked Questions (FAQ)

Common questions about Naxii (FAQ)

Q: Does Naxii have any serious long-term side effects that I should be aware of?

A: Official regulatory warnings for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Naxii describe an increased risk of serious cardiovascular (heart-related) and gastrointestinal (stomach and intestine) events. These serious risks, which include stomach bleeding, ulcers, heart attack, and stroke, are generally associated with higher doses and longer duration of use.


Q: Can Naxii cause weight gain or weight loss?

A: Weight changes are not listed among the most common adverse reactions to Naxii. However, regulatory documents state that unexplained weight gain or swelling may be a sign of fluid retention. If any unexplained weight changes or swelling occur, this information is intended for educational purposes only.


Q: Can older adults use Naxii without greater risk of side effects?

A: Official labeling indicates that older adults are generally at a greater risk for serious gastrointestinal and kidney-related adverse events compared to younger adults. Regulatory documents recommend that the use of the medicine in this population be guided by the lowest effective dose for the shortest possible duration.


Q: Is Naxii only for chronic (long-term) conditions, or can it be used short-term?

A: Official regulatory documents include specific dosing guidelines for managing both chronic conditions (which require ongoing treatment) and acute conditions (such as sudden, short-term pain). Therefore, the medicine is described as being intended for use in both long-term and short-term scenarios, based on the prescribed regimen.


Q: What types of food interactions are listed for Naxii?

A: Official administration guidelines state that Naxii should be taken orally preferably with or after food. This recommendation is intended to help minimize the possibility of gastrointestinal upset. Regulatory documents also specify a documented risk increase for serious stomach bleeding with the concurrent daily consumption of three or more alcoholic drinks.


Q: Can Naxii be taken with common pain relievers like ibuprofen or acetaminophen?

A: Official documents restrict co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen, due to a significantly increased risk of serious gastrointestinal events. No explicit warning or restriction is listed for co-use with acetaminophen, which is noted for educational purposes.


Q: What should I do if I accidentally take two doses of Naxii too close together?

A: In the event of an overdose or if the amount taken exceeds the prescribed limits, regulatory guidance states that immediate medical help should be sought. This is typically accomplished by contacting a Poison Control Center.


Q: How long does it typically take to feel any effects from Naxii?

A: The active ingredient, naproxen sodium, is the salt formulation designed for rapid and complete absorption. Pharmacokinetic studies indicate that the maximum concentration of the medicine in the blood (peak plasma levels) is generally reached in 1 to 4 hours after administration, which is consistent with the expected onset of action.


Q: Is it normal to feel a little dizzy when first starting Naxii?

A: Dizziness is listed among the common adverse reactions reported in official regulatory documents. This central nervous system effect is often reported alongside headache and nausea.


Q: Will Naxii affect my ability to drive or operate machinery?

A: Because central nervous system effects such as dizziness and drowsiness are listed as common adverse reactions in regulatory documents, official guidance recognizes that these effects may impact a person’s ability to safely drive or operate machinery.


Q: Does Naxii interact with common vitamins or supplements like Vitamin D or B12?

A: Official regulatory documents do not list any documented interactions with common vitamins such as Vitamin D or Vitamin B12. Reviewing all supplements with a healthcare professional is consistent with standard safety practice.


Q: Why do some people say Naxii makes them feel tired?

A: The central nervous system side effect of drowsiness is listed among the common adverse reactions in official regulatory documents. This effect, documented in clinical trials, may be what patients describe as feeling tired or experiencing fatigue.


Q: Can Naxii affect sleep patterns, like causing insomnia or making me drowsy?

A: Regulatory documentation notes the potential for central nervous system effects that can impact sleep. These effects include drowsiness (which is a common reported reaction) and, less frequently, insomnia (difficulty sleeping).


Q: Is it possible for Naxii to cause an allergic reaction?

A: Yes, regulatory warnings include an Allergy Alert, noting that Naxii may cause a severe allergic reaction, especially in people who are already allergic to aspirin. The listed symptoms include hives, facial swelling, asthma (wheezing), and shock.


Q: Does Naxii have a generic version available?

A: Yes, the active ingredient in Naxii, naproxen, is widely available in generic versions that have been approved by the U.S. Food and Drug Administration (FDA) and other national regulatory bodies.


Q: How long does Naxii stay in my system after the last dose?

A: Pharmacokinetic studies—which track how the body processes the medicine—indicate that the elimination half-life of naproxen ranges from 12 to 17 hours. This value represents the amount of time required for the body to reduce the concentration of the medicine by half.


Q: What is the difference between Naxii and its brand name versus its chemical name?

A: Naxii’s active ingredient is commonly referred to by its generic name, Naproxen Sodium. Its specific, highly technical chemical description, based on regulatory identifiers, is sodium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate.


Q: How does Naxii affect my heart rate or blood pressure?

A: Regulatory warnings state that NSAIDs like Naxii can cause sodium and fluid retention, which may lead to or worsen high blood pressure (hypertension) and congestive heart failure. Blood pressure monitoring is consistent with treatment using this class of medicine.


Q: Are there different strengths of Naxii available?

A: Yes, the active ingredient, naproxen sodium, is typically available in multiple common strengths for oral administration. Examples of common tablet strengths listed in official documents include 275 mg and 550 mg.


Q: Can Naxii be taken while fasting?

A: Official administration guidelines state that Naxii should be taken orally preferably with or after food. This instruction is intended to help minimize the possibility of gastrointestinal upset.


Q: What are the most commonly reported less-serious side effects of Naxii?

A: Common adverse reactions listed in regulatory documents typically relate to the gastrointestinal and central nervous systems. These include effects such as dyspepsia (indigestion), abdominal pain, nausea, headache, and dizziness.


Q: What kind of studies support the use of Naxii for its approved purpose?

A: The use of Naxii is supported by clinical studies that have established its efficacy and tolerability for its approved indications. These indications include various rheumatologic conditions like osteoarthritis, as well as acute pain and inflammatory states.


Q: How is Naxii different from the previous generation of medicines for this condition?

A: As the sodium salt formulation, Naxii is noted in regulatory documents to have a difference in its absorption. Specifically, the sodium salt allows for a more rapid absorption rate and quicker onset of action compared to the standard naproxen acid formulation.


Q: What are the most common reasons a doctor would prescribe Naxii?

A: The medicine is prescribed based on its official indications, which focus on providing symptomatic relief for conditions marked by pain, inflammation, and fever. This includes various forms of arthritis and other acute musculoskeletal pain conditions.

How should Naxii be stored and disposed of?

How to Store and Dispose of Naxii (Naproxen Sodium)

Official regulatory guidelines define specific storage and disposal requirements for Naxii tablets.

Storage Conditions

Requirement Specific Condition
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Avoid excessive heat (above 40 C), high humidity, and light exposure.
Container Store in a well-closed and light-resistant container.
Child Safety Mandatory to keep the medicine out of the reach of children.

Disposal Instructions

When disposing of unused or expired Naxii, official guidance recommends utilizing a drug take-back program or mail-back envelope. If these options are unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash; the drug is not recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naxii found in:

A-Z Index: